Saturday, October 31, 2026

AI's Short-Term Economic Impact By Prof. Ramesh Srinivasan

Via News Video

April 14, 2024

Ramesh Srinivasan, a distinguished professor at UCLA's Graduate School of Education & Information Studies with academic credentials from Stanford, MIT, and Harvard, is at the forefront of examining the interplay between technology and society through his leadership of the Digital Cultures Lab. His role extends beyond academia into the political realm, where he has significantly influenced as a member of President Biden's Innovation Policy Committee and as a supporter of Senator Bernie Sanders during the 2020 campaign, underscoring his commitment to integrating technology policy within political frameworks.

In a recent insightful interview with businessman / journalist Miguel Salvado, Srinivasan delved deep into the ongoing evolution of Artificial Intelligence and its profound implications for the economy. He articulated the challenges and opportunities that AI presents, emphasizing the necessity for individuals, businesses, and governments to adapt strategically to these technological advancements. Srinivasan's expertise provided a nuanced perspective on how AI is reshaping industries, labor markets, and societal norms, offering guidance on navigating the future of work and economic development in an increasingly digital world. This conversation highlights Srinivasan's thought leadership in understanding and shaping the trajectory of technological change and its impact on society.

In this video, Prof. Ramesh Srinivasan also talks about his experience at Web Summit, the future of AI, relevance personal data in the AI Era, identifying jobs of the future through AI, future of work, collapse of technologies, and what it means to be a human in this new AI challenge.

https://youtu.be/Z3_Ic5I1pWI
Interview by Miguel Salvado.
Via News Video

Video content and multimedia coverage from Via News, bringing you visual insights into markets, business, and finance.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com